Subscribe
Sign in
Home
Archive
Leaderboard
About
Latest
Top
Discussions
When GLP-1s become brain drugs
Doors are opening for Alzheimer's patients, for Novo, and for... Regeneron?
Sep 14
•
Ashwin Sharma, MD
28
3
Why Novo Nordisk and Eli Lilly Won't Compete on Price
But they will compete on market access and launch success
Sep 1
•
Ashwin Sharma, MD
20
5
August 2025
The $100 Billion Overreaction
how do oral GLP-1s expand the market?
Aug 24
•
Ashwin Sharma, MD
16
Why Britain’s GLP-1 Patients Are Paying for America’s Drug Politics
1.5 million become collateral damage
Aug 17
•
Ashwin Sharma, MD
11
2
Why Novo Nordisk is Out of Options (Except One)
patents become weapons
Aug 5
•
Ashwin Sharma, MD
36
23
July 2025
Are GLP-1s About to Kill the Alcohol Industry?
Change is definitely coming, but not in the way you think
Jul 13
•
Ashwin Sharma, MD
13
GLP-1s Are Quietly Killing Your Cravings (and Maybe Your Bad Habits Too)
New brain-imaging studies reveal these meds may silence the impulse engine driving addiction, compulsive behaviours, and billion-dollar snack aisles
Jul 6
•
Ashwin Sharma, MD
95
8
June 2025
Hims Has No Way Out of Their $725 Million Hole
Compounding's banned. No branded alternatives. Patent reality bites.
Jun 29
•
Ashwin Sharma, MD
6
2
How GLP-1s Are Breaking Life Insurance
Patients look healthy on paper. Two years later, they're high-risk again.
Jun 22
•
Ashwin Sharma, MD
195
33
Why Novo Nordisk Won't Beat Eli Lilly
Dividends over R&D is not a good strategy
Jun 15
•
Ashwin Sharma, MD
8
How a Tiny British Startup Became Silicon Valley's Hottest Acquisition
Tiny British startup? Hottest? How?
Jun 8
•
Ashwin Sharma, MD
6
What Do GLP-1 Patients Actually Want?
Losing weight is just the beginning
Jun 1
•
Ashwin Sharma, MD
9
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
